Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab
Kim A Papp, Andrew Blauvelt, Mary Flack, Yihua Gu, Elizabeth HZ Thompson
Abstract Not Available
Disclosures: Study supported by AbbVie.
psoriasis; risankizumab; ustekinumab; biologic therapy
Abstract - 115 Poster PDF - 65
- There are currently no refbacks.